Published in Lung Cancer on November 28, 2009
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med (2010) 1.34
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
Epigenetics of lung cancer. Transl Res (2014) 0.95
Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol (2011) 0.91
An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol (2015) 0.90
Hypermethylation of CCND2 May Reflect a Smoking-Induced Precancerous Change in the Lung. J Oncol (2011) 0.79
Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules. J Thorac Dis (2015) 0.79
Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Drug Des Devel Ther (2015) 0.78
Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clin Epigenetics (2015) 0.78
Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review. Drug Des Devel Ther (2016) 0.77
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. J Thorac Oncol (2015) 0.77
Methylation analyses in liquid biopsy. Transl Lung Cancer Res (2016) 0.75
Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer. Biol Proced Online (2017) 0.75
Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review. Oncotarget (2017) 0.75
Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA. Clin Exp Metastasis (2015) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49
Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst (1996) 4.91
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res (2001) 3.70
Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol (1993) 3.33
Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol (2005) 2.88
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol (2008) 2.71
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res (2002) 2.48
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res (2007) 2.14
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene (2002) 1.89
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer (2006) 1.78
Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg (2004) 1.77
Lung cancer in US women: a contemporary epidemic. JAMA (2004) 1.70
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 1.68
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest (2005) 1.65
Role of voltage-gated potassium channels in cancer. J Membr Biol (2005) 1.60
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol (2009) 1.58
Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res (2004) 1.57
DNA methylation profiles of lung tumors. Mol Cancer Ther (2001) 1.53
Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci (2003) 1.38
Are women more susceptible to lung cancer? J Natl Cancer Inst (2004) 1.27
Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest (2006) 1.27
Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer (2007) 1.25
Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett (2006) 1.19
Multiple inferences using confidence intervals. Clin Exp Pharmacol Physiol (2000) 1.17
Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene (2001) 1.17
DNA methylation analysis by MethyLight technology. Methods (2001) 1.15
Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis (2004) 1.14
Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res (2003) 1.12
Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer (2007) 1.11
Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist (2002) 1.09
The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers (2007) 1.09
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol (2006) 1.02
Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res (2006) 1.01
Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett (2006) 0.99
Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn (2006) 0.99
Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep (2006) 0.98
Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer (2004) 0.98
Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer (2005) 0.97
Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol (2007) 0.93
Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer (2003) 0.93
DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep (2004) 0.93
Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res (2004) 0.92
[Novel methylation and expression markers associated with breast cancer]. Mol Biol (Mosk) (2007) 0.85
Sex differences in lung-cancer susceptibility: a smoke screen? Lancet Oncol (2008) 0.85
Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol (2007) 0.81
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
PET-CT image registration in the chest using free-form deformations. IEEE Trans Med Imaging (2003) 3.79
Human L1 element target-primed reverse transcription in vitro. EMBO J (2002) 3.54
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol (2008) 2.80
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med (2002) 2.54
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Tyrosol is a quorum-sensing molecule in Candida albicans. Proc Natl Acad Sci U S A (2004) 2.39
Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21
Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 2.08
Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol (2008) 1.96
Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis (2003) 1.91
Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis (2002) 1.87
Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med (2005) 1.87
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 1.68
Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med (2005) 1.59
Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin Chem (2004) 1.50
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.48
Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst (2006) 1.47
Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer (2003) 1.46
Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev (2007) 1.43
Prevalence of sexually transmissible pathogens in semen from asymptomatic male infertility patients with and without leukocytospermia. Fertil Steril (2007) 1.40
High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis (2013) 1.38
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis (2009) 1.33
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res (2007) 1.32
p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol (2003) 1.27
Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis (2007) 1.27
Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med (2011) 1.21
The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis (2007) 1.20
FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. Semin Nucl Med (2007) 1.19
Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis (2009) 1.18
Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev (2010) 1.18
HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One (2009) 1.16
Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst (2002) 1.16
Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One (2011) 1.13
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol (2012) 1.12
Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol (2012) 1.10
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res (2011) 1.09
Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol (2005) 1.09
Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis (2009) 1.09
Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis (2008) 1.09
Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08
Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol (2004) 1.08
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol (2009) 1.06
Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. AIDS Res Hum Retroviruses (2003) 1.05
DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol (2010) 1.05
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother (2013) 1.04
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res (2012) 1.03
Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS (2006) 1.01
Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis (2008) 1.01
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer (2002) 1.01
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 0.99
Polyploidy road to therapy-induced cellular senescence and escape. Int J Cancer (2012) 0.99
Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol (2002) 0.99
Toward a stem cell gene therapy for breast cancer. Blood (2009) 0.97
An automated high-throughput counting method for screening circulating tumor cells in peripheral blood. Anal Chem (2013) 0.96
Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96